Virtual Library
Start Your Search
J. Lim
Author of
-
+
P2.01 - Poster Session with Presenters Present (ID 461)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.01-013 - HA-Liposome Nanocarrier Containing CD44 siRNA as a Targeted Chemotherapy to CD44 Related Chemoresistant Non-Small Cell Lung Cancer (ID 4188)
14:30 - 14:30 | Author(s): J. Lim
- Abstract
Background:
Chemotherapy to non-small cell lung cancer (NSCLC) remains a big limitation; chemo-resistance which has been reported regulating by one of cancer stem cells (CSC) marker cluster determinant (CD) 44 expression in NSCLC. Here, we demonstrated that the importance of CD44 in chemo-resistance of NSCLC, subsequently, develop and evaluate the hyaluronan (HA)-liposome as a drug delivery system for overcoming chemoresistance by efficiently delivery CD44 targeting siRNA to NSCLC cells.
Methods:
First, the relationship between expression of CD44 and sensitivity of the chemotherapy was evaluated in NSCLC cells (H1299, H1703, H1793, H1435, H2087, H358, H522, H460) using flow cytometry (FACS) and MTT assay. The expression of CD44 was confirmed as inversely proportion to the sensitivity of the chemotherapy in these NSCLC cells. Furthermore, in order to confirm that correlation between CD44 expression and chemo-resistance of NSCLC, we generated and characterized cisplatin resistant cell lines, and indicated that CD44 expression on resistant cells significantly increased compared to wild type cells.
Results:
Figure 1 Chemo-sensitivity of resistant cells are directly associated with expression of CD44 by knockdown of CD44 expression using siRNA. For overcoming drug-resistance in lung cancer, we developed a HA-liposome drug delivery system which can specifically target to CD44, effectively delivered CD44 siRNA to CD44 overexpressed resistant NSCLC cells. And, the HA-liposome (CD44 siRNA) successfully inhibited the expression of CD44 on resistant cells and improved the sensitivity to cisplatin.
Conclusion:
We demonstrated the corelation of chemoresistance and expression of CD44 in NSCLC, and successfully developed HA-liposome drug delivery system for significantly inhibit the expression of CD44. This study supported future investigation HA-liposome (CD44 siRNA) as possible chemotherapy carrier for targeting CD44, to assess for inhibiting chemoresistance using various drug delivery in NSCLC.
